Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s): MYCOF

Healthcare Advertising Agencies

Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The Company has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The Company is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.

CSE:MYCO - Post by User

Mydecine Innovations Group Inc

Bullboard Posts

Comment by JordanDeeon Jan 04, 2018 10:23pm

95 Views

Post# 27286473

RE:Definitive agreement will be the big deal to get signed

Agreed, the strange thing is that Stan from IR told me that "the deal is done" but no definitive agreement announced? I'll verify this tomorrow. But how else would they have paid 1.5 mil for WAK...

Bullboard Posts

Cannara reports record growth and profitability in Q4 2023